An mRNA lipid nanoparticle-incorporated nanofiber-hydrogel composite for cancer immunotherapy

一种用于癌症免疫治疗的mRNA脂质纳米颗粒掺杂纳米纤维-水凝胶复合材料

阅读:1
作者:Yining Zhu # ,Zhi-Cheng Yao # ,Shuyi Li # ,Jingyao Ma ,Christine Wei ,Di Yu ,Jessica L Stelzel ,Bobby Y X Ni ,Yang Miao ,Kyra Van Batavia ,Xiaoya Lu ,Jinghan Lin ,Yifan Dai ,Jiayuan Kong ,Ruochen Shen ,Kailei D Goodier ,Xiang Liu ,Leonardo Cheng ,Ivan Vuong ,Gregory P Howard ,Natalie K Livingston ,Joseph Choy ,Jonathan P Schneck ,Joshua C Doloff ,Sashank K Reddy ,John W Hickey ,Hai-Quan Mao
Hydrogel materials have emerged as versatile platforms for various biomedical applications. Notably, the engineered nanofiber-hydrogel composite (NHC) has proven effective in mimicking the soft tissue extracellular matrix, facilitating substantial recruitment of host immune cells and the formation of a local immunostimulatory microenvironment. Leveraging this feature, here we report an mRNA lipid nanoparticle (LNP)-incorporated NHC microgel matrix, termed LiNx, by incorporating LNPs loaded with mRNA encoding tumour antigens. Harnessing the high transfection efficiency of LNPs in antigen-presenting cells, LiNx demonstrates substantial levels of immune cell recruitment, antigen expression and presentation, and cellular interaction. These attributes collectively create an immunostimulating microenvironment and yield a potent immune response with a single dose at a level comparable to the conventional three-dose LNP immunization protocol. Further investigation reveals that the LiNx generates not only high levels of Th1 and Th2 responses, but also a distinct Type 17 T helper cell response critical for bolstering antitumour efficacy. Our findings elucidate the mechanism underlying LiNx's role in potentiating antigen-specific immune responses, presenting a strategy for cancer immunotherapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。